Xerostomia

Xerostomia is the subjective sensation of oral dryness resulting from reduced salivary gland output or altered salivary composition, and it is one of the most common oral conditions encountered in dental practice, particularly among older adult populations. The condition is most frequently caused by the pharmacological side effects of medications, with over 500 commonly prescribed drugs listing dry mouth as an adverse effect, including antihypertensives, antidepressants, antihistamines, anxiolytics, diuretics, and opioid analgesics. Other significant causes include radiation therapy to the head and neck region, which can permanently damage salivary gland tissue; autoimmune conditions such as Sjogren syndrome that target the salivary and lacrimal glands; systemic diseases including diabetes and HIV; and physiological age-related decline in salivary function.

The oral health consequences of xerostomia are substantial because saliva performs multiple protective functions including mechanical cleansing of food debris, buffering of acids produced by oral bacteria, remineralization of early enamel lesions through calcium and phosphate ion delivery, and antimicrobial activity through immunoglobulins and enzymes. When salivary flow is diminished, these protective mechanisms are compromised, and patients experience a dramatic increase in caries susceptibility, particularly rampant cervical and root surface caries in patterns not typically seen in patients with normal salivary function. Additional complications include increased susceptibility to candidal infections, difficulty wearing removable prostheses due to loss of the salivary film that supports denture retention, taste alterations, difficulty swallowing and speaking, and chronic oral mucosal soreness.

In dental practice operations, xerostomia patients represent a population that requires elevated preventive and restorative intervention, generating increased visit frequency and treatment volume. Documenting xerostomia as a diagnosed condition in the patient record establishes the clinical basis for an accelerated prophylaxis schedule, typically every three to four months rather than the standard six-month interval, and supports the medical necessity of additional fluoride treatments that might otherwise exceed plan frequency limitations. When insurance plans deny claims for more frequent preventive visits, a narrative explaining the xerostomia diagnosis, the elevated caries risk, and the clinical rationale for the increased frequency often results in overturning the denial. Prescription-strength fluoride products and saliva substitutes may be recommended as part of the complete management plan. Practices that implement a systematic screening protocol for xerostomia, including medication history review and salivary flow assessment, can identify at-risk patients proactively and develop individualized preventive plans that reduce disease progression while optimizing the revenue generated by this high-need patient population.